Oncology – Gastrointestinal
RCT | Adding Bevacizumab to trifluridine–tipiracil enhances overall survival in refractory metastatic colorectal cancer
5 May, 2023 | 15:13h | UTCTrifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD pic.twitter.com/gHTR9jbJS5
— NEJM (@NEJM) May 3, 2023
RCT | Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer
2 May, 2023 | 13:36h | UTCEfficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Heated Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer–Restarting the Fire – JAMA Surgery (free for a limited period)
Commentary on Twitter
Hyperthermic intraperitoneal chemotherapy with mitomycin C along with complete cytoreduction improved locoregional control in patients with locally advanced colorectal cancer and should be considered for treatment of locally advanced colorectal cancer. https://t.co/hOM4TvgILB
— JAMA Surgery (@JAMASurgery) April 26, 2023
Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma
28 Apr, 2023 | 13:03h | UTC
M-A | Immune checkpoint inhibitors vs. chemotherapy in the 2nd-line treatment of advanced esophageal squamous cell carcinoma
28 Apr, 2023 | 12:56h | UTC
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023
Cohort Study | Circulating tumor DNA methylation may enable early detection of recurrence in colorectal cancer
24 Apr, 2023 | 13:12h | UTCEarly Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation – JAMA Oncology (free for a limited period)
Editorial: Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time? – JAMA Oncology (free for a limited period)
Commentary on Twitter
Cohort study of 299 pts w/stage I-III colorectal cancer, evaluating ctDNA evaluation w/methylation markers, showed ctDNA before & after surgery, after adjuvant chemo, & during longitudinal monitoring is highly associated w/recurrence. https://t.co/csHNz5kWz3 #CRCSM #GICSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer
19 Apr, 2023 | 13:10h | UTCPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Kelley et al – Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)https://t.co/ZbdRQwzSuW#gitwitter #onctwitter pic.twitter.com/PwoNAduQxK
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 18, 2023
RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma
17 Apr, 2023 | 13:00h | UTCZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire
Cohort Study | Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer
17 Apr, 2023 | 12:57h | UTCCancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer – The ASCO Post
Review | Diagnostic, structured classification and therapeutic approach in cystic pancreatic lesions
12 Apr, 2023 | 12:58h | UTCRelated:
Cystic pancreatic lesions: MR imaging findings and management.
Recommendations for the management of incidental pancreatic findings in adults.
Pancreatic cystic neoplasms: a review of current recommendations for surveillance and management
Management of Pancreatic Cystic Lesions
Consensus Recommendations: Diagnosis and Surveillance of Incidental Pancreatic Cystic Lesions
Review: Pancreatic Cystic Lesions
Guidelines on pancreatic cystic neoplasms
Screening colonoscopy in seniors: common in patients with limited life expectancy and associated with higher complication risks
11 Apr, 2023 | 14:30h | UTCFrequency of Use and Outcomes of Colonoscopy in Individuals Older Than 75 Years – JAMA Internal Medicine (link to abstract – $ for full-text)
Related: Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy
Commentary:
In older adults >75 years of age, most screening colonoscopies were in patients in patients with limited life expectancy (defined as <10 years) and associated with increased risk of adverse events. https://t.co/XOsy2UKNRx @Jessica_Halabi @MRothbergMD @burkegastrodoc
— JAMA Internal Medicine (@JAMAInternalMed) April 4, 2023
SR | Risk factors for cholangitis after pancreatoduodenectomy
11 Apr, 2023 | 14:21h | UTC
Cohort Study | Impact of complications after resection of pancreatic cancer on disease recurrence and survival
10 Apr, 2023 | 13:34h | UTC
Commentary on Twitter
Major complications after?surgery are known to impair DF- and OS ➡️?of all ?? pat undergoing panc surgery 2014–2017 (n=1071) confirms via causal mediation ?that this is mediated due to omission of adjuvant CTX!https://t.co/8kjr9MpRt4#some4surgery #some4hpb @BJSAcademy pic.twitter.com/EZd7Yvi4z2
— BJS Open (@BjsOpen) April 1, 2023
Brief Review | What every gastroenterologist should know about gastrointestinal neuroendocrine tumors
4 Apr, 2023 | 13:29h | UTC
Cohort Study | Celiac axis stenosis is an underestimated risk factor for increased morbidity after pancreatoduodenectomy
4 Apr, 2023 | 13:20h | UTC
Gastric Cancer: the combined impact of H. pylori infection and pathogenic gene variants
3 Apr, 2023 | 13:51h | UTCHelicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: H. Pylori Infection Negatively Modifies Genetically Increased Risk for Gastric Cancer – Physician’s Weekly
Commentary on Twitter
Infection with Helicobacter pylori is known to confer a risk of gastric cancer. In this study, persons who carried certain genetic variants and were infected with H. pylori had an excess risk of gastric cancer. https://t.co/jIcUiYu14G#genetics pic.twitter.com/jY4H1Mq6dO
— NEJM (@NEJM) March 29, 2023
Cohort Study | Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach
3 Apr, 2023 | 13:31h | UTCLong-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach – JAMA Surgery (free for a limited period)
Invited Commentary: Guiding Patients Through a “Watch-and-Wait” Approach for Rectal Cancer—Understanding the Functional Outcomes – JAMA Surgery (free for a limited period)
Related:
Commentary on Twitter
Results of this study suggest that patients with rectal cancer who were observed by a watch-and-wait approach had good quality of life, with some patients reporting bowel and sexual dysfunction. https://t.co/zaK3bjJA8n
— JAMA Surgery (@JAMASurgery) March 31, 2023
Phase 2b RCT | Liposomal irinotecan plus fluorouracil/leucovorin for patients with previously treated metastatic biliary tract cancer
29 Mar, 2023 | 13:14h | UTCTreatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Final analysis of NIFTY trial demonstrates significant improvement of PFS & OS with use of nal-IRI plus 5-FU/LV compared to 5-FU/LV in patients with previously treated advanced biliary tract cancer. https://t.co/WrZ3GtXYxP #GICSM pic.twitter.com/BqxSbBG9dv
— JAMA Oncology (@JAMAOnc) March 23, 2023
Review | Neoadjuvant therapy for pancreatic cancer
27 Mar, 2023 | 13:02h | UTCNeoadjuvant therapy for pancreatic cancer – Nature Reviews Clinical Oncology (free for a limited period)
Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy
23 Mar, 2023 | 13:11h | UTCSummary: This study investigated the association between estimated life expectancy, surveillance colonoscopy findings, and follow-up recommendations among older adults. The study utilized data from the New Hampshire Colonoscopy Registry and included adults over 65 who underwent colonoscopy for surveillance after prior polyps.
Life expectancy was estimated using a validated prediction model and categorized into three groups: less than 5 years, 5 to less than 10 years, and 10 or more years.
Out of the 9,831 adults included in the study, 8% had advanced polyps or CRC. Among the 5,281 patients with available recommendations, 86.9% were advised to return for a future colonoscopy. Surprisingly, 58.1% of older adults with less than 5 years of life expectancy were also recommended to return for future surveillance colonoscopy.
The study concluded that many older adults with limited life expectancy are still recommended for future surveillance colonoscopy. This data could help refine decision-making about pursuing or stopping surveillance colonoscopy in older adults with a history of polyps.
Article: Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults – JAMA Internal Medicine (link to abstract – $ for full-text)
JAMA Patient Page: What Should I Know About Stopping Routine Cancer Screening?
Commentary on Twitter
Findings suggest that recommending against future surveillance colonoscopy in older adults with low-risk colonoscopy findings and/or limited life expectancy should be considered more frequently than is currently practiced. https://t.co/7jKpYyuZON
— JAMA Internal Medicine (@JAMAInternalMed) March 13, 2023
Guidelines for Gastric Cancer | An evidence-based, multidisciplinary approach
22 Mar, 2023 | 13:33h | UTC
Guidelines for post polypectomy colonoscopic surveillance
22 Mar, 2023 | 13:31h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
RCT | Comparable 5-year relapse-free survival for laparoscopic vs. open distal gastrectomy in advanced gastric cancer
22 Mar, 2023 | 13:27h | UTCSummary: The JLSSG0901 randomized clinical trial aimed to compare the 5-year survival outcomes of laparoscopy-assisted distal gastrectomy (LADG) and open distal gastrectomy (ODG) with D2 lymph node dissection for locally advanced gastric cancer.
The study involved 507 patients from 37 institutes in Japan. The primary endpoint was 5-year relapse-free survival. The results showed that the 5-year relapse-free survival rates were 73.9% and 75.7% for the ODG and LADG groups, respectively, confirming the noninferiority of LADG, and no significant differences were observed in severe postoperative complications between the two groups.
The study concluded that LADG with D2 lymph node dissection, when performed by qualified surgeons, was proven noninferior to ODG, and could become a standard treatment for locally advanced gastric cancer.
Article: Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Related:
Commentary on Twitter
Study results provide robust evidence suggesting that laparoscopic gastrectomy for locally advanced gastric cancer may be an appropriate treatment approach when performed by skilled surgeons. https://t.co/Dvnzk5YI9u pic.twitter.com/GDCdT4DJhp
— JAMA Surgery (@JAMASurgery) March 15, 2023
Review | Surveillance strategies following curative resection and non-operative approach of rectal cancer: how and how long?
15 Mar, 2023 | 14:59h | UTC